Michael Layton
Pulmonary Disease · Sebastian, FLNPI 1255430096
Payments from drug & device makers
Across 167 payments — averaging $49.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Veran Medical Technologies, Inc.$2K
- Medical Device Business Services, Inc.$481
- AstraZeneca$477
- Boehringer Ingelheim$359
- GSK$282
- plus $1K from 21 others
What the payments were for
- Travel & lodging$4,68956%
- Food & beverage$3,48442%
- Education$871%
- Other$441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 28 | $3,827 |
| Veran Medical Technologies, Inc. | 7 | $1,504 |
| Medical Device Business Services, Inc. | 6 | $481 |
| AstraZeneca | 17 | $477 |
| Boehringer Ingelheim | 22 | $359 |
| GSK | 18 | $282 |
| Grifols USA, LLC | 22 | $219 |
| Intuitive Surgical | 2 | $165 |
| Regeneron Healthcare Solutions, Inc. | 6 | $133 |
| Sanofi | 5 | $103 |
| Insmed, Inc. | 5 | $102 |
| Pulmonx Corporation | 1 | $91 |
| Merck | 6 | $87 |
| Electromed, Inc. | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 2 | $47 |
| Welch Allyn | 1 | $44 |
| United Therapeutics Corporation | 2 | $42 |
| Genentech USA, Inc. | 1 | $40 |
| Mylan Specialty L.p. | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 2 | $37 |
| Philips North America LLC | 1 | $34 |
| Shire North American Group Inc | 1 | $25 |
| Gilead | 1 | $18 |
| Circassia Inc. | 1 | $14 |
| Stryker | 1 | $14 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$3,537
- Spin$1,272
- IMFINZI$100
How this compares
$8,304 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $12,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $282 | $12,43611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Sebastian
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.